EP300

EP300 lysine acetyltransferase

Explore in graph →CI-GENE-00044818HGNC:3373 ENSG00000100393 NCBI 2033 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (3)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EP300 G1506V1
Unspecified therapy	Hodgkin LymphomaALIAS	Predictive	B	Does Not Support N/A	3	rejected

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Mesothelioma TCGA-MESO	Malignant Mesothelioma	Ssm

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.

EP300 Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11928 This study showed that CREBBP and EP300 were recurrently mutated in DLBCL PMID 21390126 · Pasqualucci et al., 2011 · Open in CIViC	civic

EP300 Y1414C1
(oncogenic)	Esophageal Squamous Cell CarcinomaALIAS	Oncogenic	D	Supports Oncogenicity	2	submitted	EID9573 Mutations in histone modifier genes were analyzed in exome sequence data from 113 esophageal squamous cell carcinoma tumors. KYSE-150 and KYSE-450 ESCC cell lines were depleted of EP300 using shRNA, t… (full text at CIViC) PMID 25151357 · Gao et al., 2014 · Open in CIViC	civic